Lilly’s Tirzepatide Cuts Type 2 Diabetes Risk By 94% in Overweight, Obese Adults

Key Points:

– Tirzepatide, a new type 2 diabetes drug, has shown promising results in reducing diabetes risk in overweight and obese adults.
– In a recent study funded by Eli Lilly and Company, patients taking Tirzepatide experienced a 94% reduction in the risk of developing type 2 diabetes.
– The study included over 8,500 participants with an average body mass index of 37, categorizing them as obese.
– Tirzepatide works by combining the actions of two hormones that regulate blood sugar levels, resulting in better glucose control and weight loss.

Hot Take:

The development of Tirzepatide offers hope for overweight and obese individuals looking to reduce their risk of type 2 diabetes. With significant results in clinical trials, this new drug could potentially revolutionize diabetes prevention and treatment. Contact Mindful Evolution at https://yourmindfulevolution.com or call or text us at 954-639-9960 for more information on how we can support you in your weight loss journey.

**Weight Loss Disclaimer: Telehealth services available in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.**